advertisement
Science News
from research organizations

New drug target for glioblastoma

Date:
August 21, 2019
Source:
Cleveland Clinic
Summary:
A new international study has identified a new drug target for treating glioblastoma. This target is part of a never-before defined cellular pathway found to contribute to the spread and proliferation of a dangerous subset of cancer cells, called glioma stem cells.
Share:
advertisement

FULL STORY

A new international study co-led by Cleveland Clinic has identified a new drug target for treating glioblastoma. This target is part of a never-before defined cellular pathway found to contribute to the spread and proliferation of a dangerous subset of cancer cells, called glioma stem cells.

While previous research has shown that a protein called FGF2 (fibroblast growth factor 2), when activated ("turned on"), contributes to glioma stem cell self-renewal and tumor growth, it was not understood how. This study, co-led by Justin Lathia, Ph.D., Cleveland Clinic Lerner Research Institute, identifies FGF2 as an important intermediary in a multi-step, pro-cancer signaling loop and suggests that "turning off" FGF2 may halt the growth and spread of glioblastoma.

Published in the August 21 issue ofCancer Discovery, this study is the first to identify FGF2 as a novel druggable target for glioblastoma, the most common primary malignant brain tumor. With standard treatment, the median survival for adults with glioblastoma is only between 11 and 15 months, and recurrence is very common. New therapies are greatly needed.

Extracellular matrix (ECM) is a network of molecules that -- like brick and mortar -- help to hold and anchor nearby cells together. The research team found that a protein called ADAMDEC1 (a disintegrin and metalloproteinase domain-like protein decysin 1), which is secreted by glioma stem cells, breaks down ECM. In its absence, cancer cells are able to access key nutrients for their growth that otherwise would not be available.

One of these nutrients is FGF2. The team of researchers showed that ADAMDEC1 activates FGF2, which is found within the tumor microenvironment. Like a lock and key, the "turned on" FGF2 selectively binds to and activates a receptor found on the surface of glioma stem cells, called FGFR1 (FGF receptor 1).

FGFR1, mediated through a few additional signaling cascades, plays two important roles in driving glioblastoma. It helps to mediate the hallmark pro-cancer characteristics of glioma stem cells, including their ability to self-renew and spread. Additionally, FGFR1 signaling ultimately induces the expression of ADAMDEC1, which sends this whole cellular feedback loop into motion again.

"These findings are exciting because they put forth a new paradigm for glioma stem cell regulation," said Dr. Lathia. "This pathway shows that glioma stem cells' ability to access key nutrients in their surrounding microenvironment, by way of ADAMDEC1, is integral for their maintenance and spread. Finding a way to interrupt this feedback loop will be important for treating glioblastoma."

While additional research is necessary, this study suggests that therapeutically targeting FGF2 may be the key to interrupting this cancer-driving loop.

advertisement

Story Source:

Materials provided byCleveland Clinic.注意:内容可能被编辑风格d length.


Journal Reference:

  1. Ana Jimenez-Pascual, James S Hale, Anja Kordowski, Jamie Pugh, Daniel J Silver, Defne Bayik, Gustavo Roversi, Tyler j Alban, Shilpa Rao, Rui Chen, Thomas M McIntyre, Giorgio Colombo, Giulia Taraboletti, Karl O Holmberg, Karin Forsberg-Nilsson, Justin D Lathia and Florian A Siebzehnrubl.ADAMDEC1 maintains a growth factor signaling loop in cancer stem cells.Cancer Discovery, 2019 DOI:10.1158/2159-8290.CD-18-1308

Cite This Page:

Cleveland Clinic. "New drug target for glioblastoma." ScienceDaily. ScienceDaily, 21 August 2019. .
Cleveland Clinic. (2019, August 21). New drug target for glioblastoma.ScienceDaily. Retrieved June 27, 2023 from www.koonmotors.com/releases/2019/08/190821100007.htm
Cleveland Clinic. "New drug target for glioblastoma." ScienceDaily. www.koonmotors.com/releases/2019/08/190821100007.htm (accessed June 27, 2023).

Explore More
from ScienceDaily

RELATED STORIES

advertisement